Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20153494 | 1.00 | HTT (0.43) | HTTATMDDB1CRBNMAPT | |
| SCHEMBL17865739 | 1.00 | HTT (0.43) | HTTATMDDB1CRBNMAPT | |
| SCHEMBL17865748 | 1.00 | HTT (0.43) | HTTATMDDB1CRBNMAPT | |
| SCHEMBL19521244 | 0.88 | NR1H2 (0.40) | DDB1CRBNMAPTKDM4ETHRB | |
| SCHEMBL19521200 | 0.88 | NR1H2 (0.40) | DDB1CRBNMAPTKDM4ETHRB | |
| SCHEMBL19521196 | 0.88 | NR1H2 (0.40) | DDB1CRBNMAPTKDM4ETHRB | |
| SCHEMBL19541286 | 0.88 | NR1H2 (0.40) | DDB1CRBNMAPTKDM4ETHRB | |
| SCHEMBL20153495 | 0.84 | HRH3 (0.33) | ADAM17ADAMTS5 | |
| SCHEMBL17865755 | 0.84 | HRH3 (0.33) | ADAM17ADAMTS5 | |
| SCHEMBL17969610 | 0.84 | HRH3 (0.33) | ADAM17ADAMTS5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250057808-A1 | COMPOSITION COMPRISING BETA LACTAM FOR TREATING ALCOHOL DEPENDENCE AND ALCOHOL ASSOCIATED DISEASES OR CONDITIONS | UNIVERSITY OF TOLEDO | 2025-02-20 | — | — | US | claimed |
| US-9975879-B2 | Beta lactams as modulators of glutamate uptake and methods for use thereof | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2018-05-22 | — | — | US | claimed |
| WO-2016184911-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF THE NEUROPATHOLOGY OF PATIENTS SUFFERING FROM MYOTONIC DYSTROPHY TYPE 1 (DM1) | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2016-11-24 | — | — | WO | claimed |
| US-20160229841-A1 | NOVEL BETA LACTAMS AS MODULATORS OF GLUTAMATE UPTAKE AND METHODS FOR USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-08-11 | — | — | US | claimed |
| EP-3036219-A2 | NOVEL BETA LACTAMS AS MODULATORS OF GLUTAMATE UPTAKE AND METHODS FOR USE THEREOF | Temple University Of The Commonwealth System Of Higher Education (US) | 2016-06-29 | — | — | EP | claimed |
| US-20250057808-A1 | COMPOSITION COMPRISING BETA LACTAM FOR TREATING ALCOHOL DEPENDENCE AND ALCOHOL ASSOCIATED DISEASES OR CONDITIONS | UNIVERSITY OF TOLEDO | 2025-02-20 | — | — | US | disclosed |
| US-9975879-B2 | Beta lactams as modulators of glutamate uptake and methods for use thereof | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2018-05-22 | — | — | US | disclosed |
| US-9975879-B2 | Beta lactams as modulators of glutamate uptake and methods for use thereof | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2018-05-22 | — | — | US | disclosed |
| US-9975879-B2 | Beta lactams as modulators of glutamate uptake and methods for use thereof | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2018-05-22 | — | — | US | disclosed |
| WO-2016184911-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF THE NEUROPATHOLOGY OF PATIENTS SUFFERING FROM MYOTONIC DYSTROPHY TYPE 1 (DM1) | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2016-11-24 | — | — | WO | disclosed |
| US-20160229841-A1 | NOVEL BETA LACTAMS AS MODULATORS OF GLUTAMATE UPTAKE AND METHODS FOR USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-08-11 | — | — | US | disclosed |
| US-20160229841-A1 | NOVEL BETA LACTAMS AS MODULATORS OF GLUTAMATE UPTAKE AND METHODS FOR USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-08-11 | — | — | US | disclosed |
| US-20160229841-A1 | NOVEL BETA LACTAMS AS MODULATORS OF GLUTAMATE UPTAKE AND METHODS FOR USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250057808-A1 | COMPOSITION COMPRISING BETA LACTAM FOR TREATING ALCOHOL DEPENDENCE AND ALCOHOL ASSOCIATED DISEASES OR CONDITIONS | ADH1A, ADH1C, SLC10A1 | HTT 3710/4885ATM 3557/4885DDB1 4314/4885 |
| US-20160229841-A1 | NOVEL BETA LACTAMS AS MODULATORS OF GLUTAMATE UPTAKE AND METHODS FOR USE THEREOF | SLC1A2, SLC7A11, SLC18A2 | HTT 2026/4885ATM 4358/4885DDB1 3086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.